>BOSTON (Reuters) – A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company’s victims.
U.S. District Judge William Young in Boston had in November rejected an initial plea deal between the U.S. Justice Department and the Novelion Therapeutics Inc unit, saying it restricted his ability to impose a sentence.
